Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | NME4 | O00746 | 3/20 | 0.65 |
| ▸ | GCDH | Q92947 | 3/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.65 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | BLVRB | P30043 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL29352778 | 1.00 | SIRT5 (0.65) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL29383212 | 0.99 | SIRT5 (0.67) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL30360 | 0.99 | SIRT5 (0.67) | SIRT5TDP1NME4GCDHADORA3 | |
| SCHEMBL11168262 | 0.88 | TDP1 (0.61) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL29515073 | 0.82 | SIRT5 (0.61) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL1461533 | 0.81 | ADORA3 (0.52) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL133200 | 0.80 | SIRT5 (0.95) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL118300 | 0.79 | SIRT5 (1.00) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL3267109 | 0.79 | SIRT5 (1.00) | SIRT5TDP1NME4GCDHADORA3 | |
| Balsalazide SCHEMBL138311 | 0.79 | SIRT5 (1.00) | SIRT5TDP1NME4GCDHADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4889 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12053447-B2 | Oral solution and powder to liquid compositions of balsalazide | NuBioPharma, LLC (US) | 2024-08-06 | — | — | US | claimed |
| CN-118141602-A | Lacrimal canaliculus embolism | 上海曙瑞科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-113970607-B | Detection method of related substances in balsalazide sodium capsules | 马应龙药业集团股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4335413-A2 | PROSTHETIC TISSUE VALVES | Cormatrix Cardiovascular, Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2023212179-A2 | THERAPEUTIC COMPOSITIONS FOR SKIN DISORDERS AND WOUND REPAIR | UNIVERSITY OF MIAMI (US) | 2023-11-02 | — | — | WO | claimed |
| CN-219390322-U | Balsalazide sodium intermediate reactant drying device | 大连万福制药有限公司 | 2023-07-21 | — | — | CN | claimed |
| CN-116271060-A | Pharmaceutical composition, preparation method and application thereof | 优畅达(武汉)医疗科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2003088811-A2 | GELSOLIN AS A PROGNOSTIC MARKER OF ARTHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030152566-A1 | Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-08-14 | — | — | US | claimed |
| WO-2003040691-A2 | SOLUBLE CD40L(CD154) AS A PROGNOSTIC MARKER OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | claimed |
| EP-1212101-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2001525058-A | — | — | 2001-12-04 | — | — | JP | claimed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1003501-A4 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM & WOMENS HOSPITAL (US) | 2001-01-17 | — | — | EP | claimed |
| EP-1003501-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1998043630-A1 | MEANS OF ASCERTAINING AN INDIVIDUAL'S RISK PROFILE FOR ATHEROSCLEROTIC DISEASE | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 1998-10-08 | — | — | WO | claimed |